These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33710336)

  • 1. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation.
    Baumrin E; Izaguirre NE; Bausk B; Feeley MM; Bay CP; Yang Q; Ho VT; Baden LR; Issa NC
    Blood Adv; 2021 Mar; 5(6):1585-1593. PubMed ID: 33710336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
    López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
    Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
    Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
    Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
    Vink P; Delgado Mingorance I; Maximiano Alonso C; Rubio-Viqueira B; Jung KH; Rodriguez Moreno JF; Grande E; Marrupe Gonzalez D; Lowndes S; Puente J; Kristeleit H; Farrugia D; McNeil SA; Campora L; Di Paolo E; El Idrissi M; Godeaux O; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
    Cancer; 2019 Apr; 125(8):1301-1312. PubMed ID: 30707761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
    Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
    Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
    J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
    Bastidas A; de la Serna J; El Idrissi M; Oostvogels L; Quittet P; López-Jiménez J; Vural F; Pohlreich D; Zuckerman T; Issa NC; Gaidano G; Lee JJ; Abhyankar S; Solano C; Perez de Oteyza J; Satlin MJ; Schwartz S; Campins M; Rocci A; Vallejo Llamas C; Lee DG; Tan SM; Johnston AM; Grigg A; Boeckh MJ; Campora L; Lopez-Fauqued M; Heineman TC; Stadtmauer EA; Sullivan KM;
    JAMA; 2019 Jul; 322(2):123-133. PubMed ID: 31287523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
    Curran D; Matthews S; Rowley SD; Young JH; Bastidas A; Anagnostopoulos A; Barista I; Chandrasekar PH; Dickinson M; El Idrissi M; Heras I; Milliken ST; Monserrat Coll J; Navarro Matilla MB; Oostvogels L; Piątkowska-Jakubas B; Quiel D; Sabry W; Schwartz S; Selleslag DLD; Sullivan KM; Theunissen K; Yegin ZA; Yeh SP; Zaja F; Szer J;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2474-2481. PubMed ID: 31394276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
    Schmader KE; Levin MJ; Chen M; Matthews S; Riley ME; Woo W; Hervé C; Grupping K; Schuind AE; Oostvogels L; Curran D
    J Gerontol A Biol Sci Med Sci; 2021 Feb; 76(3):485-490. PubMed ID: 32530462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
    McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
    Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
    van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
    BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
    Kim JH; Diaz-Decaro J; Jiang N; Hwang SJ; Choo EJ; Co M; Hastie A; Hui DSC; Irimajiri J; Lee J; Leung EM; Tang H; Tsuru T; Watson P; Wu Z; Yu CJ; Yuan Y; Zahaf T; Cunningham AL; Schuind A
    Hum Vaccin Immunother; 2021 Jul; 17(7):2050-2057. PubMed ID: 33606577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    Dagnew AF; Klein NP; Hervé C; Kalema G; Di Paolo E; Peterson J; Salaun B; Schuind A
    J Infect Dis; 2021 Oct; 224(7):1139-1146. PubMed ID: 32103273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.